


# sam<sup>®</sup> Pro 2.0

The most advanced wearable and durable sustained acoustic medicine device to naturally accelerate soft tissue repair and reduce chronic pain.



## Highlighted New Features for sam<sup>®</sup> Pro 2.0

- **Power Controller:** The 2.0 device features up to 4x faster rapid capability over existing sam<sup>®</sup> devices along with improved ergonomics and button-strength. The military-medical-grade housing is coated with a molded label, and each system is uniquely serialized with laser engraving. Additional features include data-capture and treatment history monitoring upgrades\*.
- **Applicators:** Design innovation leading to improved ultrasound delivery performance is the hallmark of sam<sup>®</sup> Pro 2.0. Thermally conductive transfer layers, thermoplastic design and smart treatment monitoring improve ultrasound delivery performance. Rugged in mold label housings with key-lock feature between applicator and y-adapter provide easy and secure wire connections.
- **Coupling Patches:** New custom stretch and hypoallergenic patches feature 3M Science Applied to Life<sup>™</sup> technology. In addition to improved wear performance, 2.0 patches are easier to use and less messy with the patented gel-capture seals.



Specification Sheet sam<sup>®</sup> Pro 2.0 is a class II medical device



**Durable carrying case with component, charger and accessory space**



**Active-wear neoprene arm band**



**sam<sup>®</sup> Pro 2.0 device MSRP \$5,800.00 includes:**

- Power controller with belt clip
- Dual applicators with Y-adapter
- Rapid 2-amp USB charger
- Arm-band
- 2-Oz. Tube of Ultrasound Gel
- User manual and quick start guide
- 1-year full system warranty

Made and designed in the U.S.A by ZetroZ Systems, LLC.  
Trumbull, CT 06611  
USA/PCT Patents 9,492,687; 9,480,863; 9,199,096; D746,994; D732,673; D732,672; D730,883. Additional patents pending. All rights reserved © 2018

\*For commercial accounts only. Discuss upgrade features with your sam<sup>®</sup> account representative



# sam<sup>®</sup> Pro 2.0

Clinical evidence supports the use of sam<sup>®</sup> on a daily basis for the treatment of back pain from strain and disk herniation, joint pain from cartilage damage and arthritis, and tendon pain from overuse and injury.




Clinical Evidence  
Summary and Treatment  
Guide Update


## New Highlighted Clinical and Scientific Evidence sam<sup>®</sup> Pro 2.0

- Upper and Lower Back Pain:** In a 33-patient, 4-week randomized sham controlled study (RCT) on chronic upper back pain, active sam<sup>®</sup> provided a significant reduction in pain on the visual analogue scale (VAS). Pain was reduced by 2.15-points VAS (\*40.0%) versus sham group 0.88-points VAS (17.4%) ( $p < 0.05$ ). The global rate of change score was also significantly better for the active treatment group (+2.84-points) versus (+0.46-points) for the sham group ( $p < 0.01$ ).
- In another recently completed 65-patient, 8-week RCT, sam<sup>®</sup> reduced pain by 2.08-points VAS (30.4%).

Pre/Post sam<sup>®</sup> Treatment Upper Back Pain




- Osteoarthritis Joint Pain:** In a 90-patient, 6-week, RCT on knee osteoarthritis pain sam<sup>®</sup> significantly reduced joint pain by 2.03-points VAS (\*37.1%) versus sham treatment 1.02-points VAS (20.2%) ( $p < 0.05$ ). Additionally, the Western Ontario McMaster Osteoarthritis Questionnaire (WOMAC) score was significantly improved for all measures of pain, function and stiffness in the active treatment group. Active sam<sup>®</sup> treatment showed a 505-point WOMAC improvement versus a 266-point WOMAC for sham ( $p < 0.01$ ).



Twelve (+12) Clinical Studies Support sam<sup>®</sup> Pro 2.0 Treatment

### Osteoarthritis Pain Reduction



sam<sup>®</sup> research is funded by the following United States government agencies: National Institutes of Health, US Department of Defense, National Science Foundation, National Air and Space Agency, and private funding from foundations and industry partners. All rights reserved © 2018.

